Pulmoten Tablet 62.50 mg
Pulmoten Tablet 62.50 mg Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | Pulmoten Tablet 62.50 mg |
| Generic | Bosentan Monohydrate |
| Weight | 62.50 mg |
| Type | Tablet |
| Therapeutic Class | Anti-hypertensive, Endothelin receptor antagonist |
| Manufacturer | UniMed UniHealth Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class Ill. Efficacy has been shown in: Some improvements have also been shown in patients with PAH WHO functional class ll.Dosage
Pulmoten Tablet 62.50 mg dosage
Tablets are to be taken orally morning and evening, with or without food.Pulmonary arterial hypertension: ln adult patients, Bosentan treatment should be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily.For paediatric patients aged 2 years or older, the optimal maintenance dose has not been defined in well-controlled studies. However, paediatric pharmacokinetic data have shown that Bosentan plasma concentrations in children were on average lower than in adult patients and were not increased by increasing the dose of Bosentan above 2 mg/kg body weight twice daily.Discontinuation of treatment: lf the decision to withdraw Bosentan is taken, it should be done gradually while an alternative therapy is introduced.Side Effects
Treatment with bosentan has been associated with dose dependent elevations in liver aminotransferases and decreases in haemoglobin concentration. Other side effects include Anaemia, haemoglobin decrease, Thrombocytopenia, Neutropenia, leucopenia, Hypersensitivity reactions, Headache, Syncope, Palpitations, Flushing, Hypotension, Gastroesophageal reflux disease, Aminotransferase elevations associated with hepatitis and/or jaundice, Liver cirrhosis, liver failure (rarely), Erythema, Diarrhoea, Oedema, fluid retention.Precaution
Consider discontinuation of therapy if pulmonary oedema occurs. Avoid abrupt withdrawal and consider dose reduction (e.g. half the dose for 3-7 days) to minimise risk of clinical deterioration. Lactation. Bosentan may cause dizziness, which could affect the ability to drive or use machines.Interaction
Increased bosentan levels with CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, diltiazem), CYP2C9 inhibitors (e.g. amiodarone, fluconazole), tacrolimus. Rifampicin initially increases but subsequently decreases bosentan concentration. May decrease plasma levels of warfarin, statins (e.g. simvastatin, lovastatin), hormonal contraceptives, sildenafil, tadalafil.Pregnancy & Breastfeeding use
Bosentan is contraindicated in pregnancy. lt is not known whether bosentan is excreted into human breast milk. Breast-feeding is not recommended during treatment with Bosentan.Contraindication
Hypersensitivity to the active substance or to any of the excipients Moderate to severe hepatic impairment, i.e., Child-Pugh class B or C. Baseline values of liver aminotransferases, i.e., aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT), greater than 3 times the upper limit of normal Concomitant use of cyclosporine A. Pregnancy Special warnings and precautions for use Liver aminotransferase levels must be measured prior to initiation of treatment and subsequently at monthly intervals for the duration of treatment with Bosentan. ln addition, liver aminotransferase levels must be measured 2 weeks after any dose increase.Special Warning
Dosage in hepatic impairment: No dose adjustment is needed in patients with mild hepatic impairment. Bosentan is contraindicated in patients with moderate to severe liver dysfunction.Dosage in renal impairment: No dose adjustment is required in patients with renal impairment. No dose adjustment is required in patients undergoing dialysis.Dosage in elderly patients: No dose adjustment is required in patients over the age of 65 years.Hepatic impairment: ln patients with mildly impaired liver function (Child-Pugh class A) no relevant changes in the pharmacokinetics have been observed. The pharmacokinetics of Bosentan have not been studied in patients with Child-Pugh class B or C hepatic impairment and Pulmoten is contra-indicated in this patient population.Renal impairment: No dose adjustment is required in patients with renal impairment. There is no specific clinical experience in patients undergoing dialysis. Based on physicochemical properties and the high degree of protein binding, bosentan is not expected to be removed from the circulation by dialysis to any significant extent.Storage Condition
Store below 30°C. Store in a cool and dry place, protected from light. Keep out of children’s reach.Innovators Monograph
You find simplified version here Pulmoten Tablet 62.50 mg
